Director/PDMR Shareholding

RNS Number : 7174B

Allergy Therapeutics PLC

20 April 2012

 



20 April 2012

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

PDMR/Director Shareholding

Allergy Therapeutics plc (AIM: AGY) announces that pursuant to the fundraising announced on 30 March 2012, which completed yesterday, the Directors of the Company have the following holdings in the Company:

Name of Director	Number of Ordinary Shares	Percentage of Issued Share Capital
Peter Jensen	120,000	0.03%
Manuel Llobet(1)	3,125,000	0.77%
Ian Postlethwaite	493,000	0.12%
Stephen Smith	776,513	0.19%
Alejandro Weinstein Jr.(1)	201,986,132	49.64%
Ignace Goethals	5,033,109	1.24%
Virinder Nohria	532,160	0.13%

(1)  Manuel Llobet and Alejandro Weinstein Jr. are members of the Concert Party described in the Circular. Further details of the Concert Party and their interests in the Company are set out in the Circular sent to Shareholders on 30 March 2012 and in a separate announcement released today via RNS.

Capitalised terms used, but not defined in this announcement, shall have the same meaning as given to them in the announcement and Circular published by the Company on 30 March 2012.

For further information:

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
FTI Consulting	[phone]
Jonathan Birt/ Susan Quigley/ Simon Conway

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

 

END

 

 

RDSBLGDSLXBBGDC